AI Article Synopsis
- HCV NS5A inhibitors, like MK-8325, have demonstrated strong effectiveness in lab tests for treating hepatitis C virus (HCV)
- MK-8325 is a new drug that combines silyl proline and targets the NS5A protein, showing broad effectiveness across different HCV genotypes
- The drug also has favorable absorption and distribution characteristics, making it a promising candidate for oral treatment combinations
Article Abstract
HCV NS5A inhibitors have shown impressive in vitro potency profiles in HCV replicon assays thus making them attractive components for inclusion in an all oral fixed dose combination regimen. Herein, we describe the discovery and characterization of silyl proline-containing HCV NS5A inhibitor MK-8325 with good pan-genotype activity and acceptable pharmacokinetic properties.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.bmcl.2018.03.049 | DOI Listing |
Publication Analysis
Top Keywords
silyl proline-containing
8
ns5a inhibitor
8
pan-genotype activity
8
hcv ns5a
8
mk-8325 silyl
4
proline-containing ns5a
4
inhibitor pan-genotype
4
activity treatment
4
hcv
4
treatment hcv
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!